Chuo-ku, Japan

Machiko Shiroishi

USPTO Granted Patents = 2 



Average Co-Inventor Count = 14.0

ph-index = 1


Company Filing History:


Years Active: 2022-2024

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Machiko Shiroishi: Innovator in Pharmaceutical Chemistry

Introduction

Machiko Shiroishi is a prominent inventor based in Chuo-ku, Japan. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that have therapeutic potential. With a total of two patents to her name, her work is recognized for its innovative approach to drug development.

Latest Patents

Shiroishi's latest patents focus on cycloalkane-1,3-diamine derivatives. These compounds are designed to inhibit the interaction between menin and an MLL protein, which is crucial in various biological processes. The patents detail a compound or a pharmaceutically acceptable salt thereof, represented by a specific formula. The intricate details of the formula include various components defined in the patent description, showcasing her expertise in chemical innovation.

Career Highlights

Machiko Shiroishi is currently employed at Daiichi Sankyo Company, Limited, a leading pharmaceutical company. Her role involves extensive research and development, contributing to the advancement of new therapeutic agents. Her work has not only enhanced her professional reputation but has also played a vital role in the company's innovative projects.

Collaborations

Shiroishi collaborates with esteemed colleagues, including Kenji Yoshikawa and Noriyasu Haginoya. These partnerships foster a dynamic research environment, allowing for the exchange of ideas and expertise that drive innovation in their projects.

Conclusion

Machiko Shiroishi stands out as a dedicated inventor in the pharmaceutical industry. Her contributions through her patents and collaborations reflect her commitment to advancing medical science. Her work continues to inspire future innovations in drug development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…